TMCI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Treace Medical Concepts Inc (TMCI) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock lacks clear positive catalysts, has bearish technical indicators, and no strong trading signals. While the company has shown revenue growth, its profitability remains negative, and analysts have lowered price targets. Waiting for the upcoming earnings report on February 27, 2026, may provide more clarity on the company's future performance.
The technical indicators suggest a bearish trend. The MACD is negative and expanding, RSI is neutral at 23.372, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 1.941), with resistance at R1: 2.346. There is no clear signal for a reversal or upward momentum.
The company is targeting a large market of 67 million Americans with its Lapiplasty®3D Bunion Correction System, which could drive future growth. Revenue increased by 11.37% YoY in Q3 2025.
Gross margin dropped by 1.34% YoY. Analysts have lowered the price target from $4 to $3, citing concerns about near-term narratives. The MACD and moving averages indicate a bearish trend.
In Q3 2025, revenue increased by 11.37% YoY to $50.21M, but net income remained negative at -$16.29M, albeit improving by 6.04% YoY. EPS improved slightly to -0.26, up 4.00% YoY. Gross margin declined to 79.07%, down 1.34% YoY.
Analyst Richard Newitter from Truist lowered the price target from $4 to $3 and maintained a Hold rating. The analyst is cautiously optimistic about the MedTech sector but sees limited near-term catalysts for TMCI.
